The proposed rule will reduce drug costs for states and the government alike, according to a May 23 news release from CMS.
Here are the three main provisions of the proposal:
- Giving CMS and states a drug price verification tool to establish why certain drugs are higher cost to facilitate better negotiating between states and manufacturers.
- Requiring transparent reporting of drug payment information among third-party contractors such as pharmacy benefit managers.
- Increasing transparency in how drugs are classified as either brand name or generic to ensure states get rebates to which they are entitled and giving states the ability to verify that manufacturers properly classify their outpatient drugs.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.